BioSpace News Archive

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced that management will present an update on the Company’s business at the 2023 Cantor Global Healthcare Conference on Tuesday, September 26, 2023 at 4:55 p.m. Eastern Time in NYC.

Envoy Medical® Corporation (“Envoy”), a hearing health company, today announced the proposed slate of seven directors to be voted on during the special meeting of stockholders to be held by its merger partner

Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the virtual Gilmartin Group Emerging Growth Company Showcase.

PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (“PharmaDrug” or the “Company”), announced today that, further to its press release dated September 6, 2023, Mr. Daniel Cohen will not be standing for re-election as a director

HilleVax, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, announced the pricing of its public offering of 8,000,000 shares of its common stock at an initial price to the public of $12.50 per share.

Everest Medicines announced that the Center for Drug Evaluation of the China National Medical Products Administration has recommended Priority Review for cefepime-taniborbactam for the treatment of complicated urinary tract infections, including pyelonephritis, based on the criteria of “innovative drugs for the prevention and treatment of major infectious diseases and rare diseases that meet urgent clinical needs.”

EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies, is pleased to announce that the company will present the first-in-human results for EMB-02 as a poster display at the 2023 European Society for Medical Oncology (ESMO) Congress on October 23 (local time).

Bioventus Inc. announced that Mark Singleton, senior vice president and chief financial officer, will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 28, 2023, at 1:50 p.m. ET.

PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company announced a new multi-target collaboration and license agreement with U.S.-based Genentech, a member of the Roche Group, focused on the discovery and development of novel macrocyclic peptide-radioisotope drug conjugates.

ARS Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration issued a Complete Response Letter regarding its New Drug Application for neffy® in the treatment of Allergic Reactions, including anaphylaxis for adults and children ≥30 kg. ARS Pharma plans to submit a Formal Dispute Resolution Request to appeal the issuance of this CRL.